Antihypertensives Dominate The Chronic Kidney Disease Drugs Market
The global market for chronic kidney disease drugs is expected to witness single-digit growth during 2019–2025. The drug pipeline of chronic kidney disease looks promising with novel therapeutic approaches, such as cell therapy, likely to enhance the market growth opportunities. However, the competition from biosimilars and complex drug development processes are impeding the market growth.
Over the period, extensive research is being done to fill the unmet needs’ gap. The advances in the arena of regenerative treatment have come up with budding advancement of cell therapies that help regeneration and repairing of the kidneys. Cell therapy is proficient of refining the fundamental functioning capability of the kidney. Uncontrolled high blood pressure and diabetes are the leading causes of kidney failure globally.
North America dominates the global chronic kidney disease drugs market, followed by Asia Pacific and Europe. The significant share of the North America market is from the US. In the US, CKD implies an enormous cost burden, costing Medicare about $65 billion annually for CKD care and management, and an additional $34 billion associated with patients for dialysis care. Asia Pacific is projected to offer lucrative growth opportunities to market players on the grounds of the rising expenditure on healthcare, infrastructural advancements in the healthcare industry, and the growing focus on community healthcare.
Access Full Report Summary @ https://www.infoholicresearch.com/report/chronic-kidney-disease-drugs-market/?utm_source=pravinmane&utm_campaign=LG